Market Research Reports and Industry Reports

Oncternal Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab and TK216. The companys pipeline compounds are primarily focused on exciting targets which are uniquely expressed within cancer cells. Oncternal addresses different medical challenges from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T). Its Cirmtuzumab is currently in a phase 1 trial for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The company has academic collaborations to identify and develop novel research approaches. Oncternal is headquartered in San Diego, California, the US.

Oncternal Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Merger 20
Oncternal Therapeutics Merges with Tokalas 20
Licensing Agreements 21
Oncternal Therapeutics Enters into Licensing Agreement with University of California 21
Oncternal Therapeutics Inc - Key Competitors 22
Oncternal Therapeutics Inc - Key Employees 23
Oncternal Therapeutics Inc - Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Product Approvals 25
Jul 13, 2016: TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer 25
Jun 20, 2016: Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma 26
Clinical Trials 27
Aug 30, 2016: Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List Of Tables


Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncternal Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Oncternal Therapeutics Merges with Tokalas 20
Oncternal Therapeutics Enters into Licensing Agreement with University of California 21
Oncternal Therapeutics Inc, Key Competitors 22
Oncternal Therapeutics Inc, Key Employees 23

List Of Figures


Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Oncternal Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab

USD 250View Report

Respira Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Respira Therapeutics Inc (Respira) is a provider of dry powder inhaler technologies. The company develops robust portfolio of inhaled drug products for orphan pulmonary diseases. Its products under development are

USD 250View Report

Blackthorn Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Blackthorn Therapeutics Inc (Blackthorn Therapeutics) is a clinical-stage biopharmaceutical company which discovers and develops novel targeted treatments for neurobehavioral disorders. The company is building pipeline of small molecule modulates which

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Aug 2017
No. of Pages :28
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
pendik escort tuzla escort antalya escort bayan kartal escort
instagram takipci hilesi
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop